Sandoz Group (SDZ) Stock Overview
Develops, manufactures, and markets generic and biosimilars worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SDZ from our risk checks.
SDZ Community Fair Values
Create NarrativeSee what 62 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sandoz Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 68.62 |
| 52 Week High | CHF 75.90 |
| 52 Week Low | CHF 43.86 |
| Beta | 0.49 |
| 1 Month Change | -7.40% |
| 3 Month Change | 1.03% |
| 1 Year Change | 43.95% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 181.81% |
Recent News & Updates
Narrative Update • Sep 17
SDZ: Biosimilar Expansion Plans Will Shape Future Earnings Power Profile
The analyst price target for Sandoz Group has been revised higher to CHF 74.95 from CHF 72.48, reflecting updated assumptions on revenue growth, profitability and future P/E, in line with recent target increases from CHF 66 to CHF 72 and from CHF 75 to CHF 80 cited by analysts. Analyst Commentary Recent target moves around Sandoz Group give you a sense of how analysts are weighing the company’s execution against its current valuation.Narrative Update • Sep 03
SDZ: Biosimilar Expansion And Margin Shift Will Guide Future P/E Profile
Analysts have lifted the fair value estimate for Sandoz Group, with the implied price target moving higher by CHF 1.74 to CHF 72.48. They cite updated assumptions on discount rate, revenue growth, profit margins and future P/E that align with recent Street research pointing to a CHF 80 target.
Narrative Update • Aug 16
SDZ: Brazil Diabetes Entry And Legal Settlements Will Still Restrain Earnings Multiple
Analysts have lifted the Sandoz Group price target by CHF 5 to CHF 80, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News for Sandoz Group Sandoz Group agreed US settlements totaling US$478.5 million related to generic drug pricing investigations, reducing a long running source of legal uncertainty.Recent updates
Narrative Update • Sep 17
SDZ: Biosimilar Expansion Plans Will Shape Future Earnings Power Profile
The analyst price target for Sandoz Group has been revised higher to CHF 74.95 from CHF 72.48, reflecting updated assumptions on revenue growth, profitability and future P/E, in line with recent target increases from CHF 66 to CHF 72 and from CHF 75 to CHF 80 cited by analysts. Analyst Commentary Recent target moves around Sandoz Group give you a sense of how analysts are weighing the company’s execution against its current valuation.Narrative Update • Sep 03
SDZ: Biosimilar Expansion And Margin Shift Will Guide Future P/E Profile
Analysts have lifted the fair value estimate for Sandoz Group, with the implied price target moving higher by CHF 1.74 to CHF 72.48. They cite updated assumptions on discount rate, revenue growth, profit margins and future P/E that align with recent Street research pointing to a CHF 80 target.Narrative Update • Aug 16
SDZ: Brazil Diabetes Entry And Legal Settlements Will Still Restrain Earnings Multiple
Analysts have lifted the Sandoz Group price target by CHF 5 to CHF 80, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News for Sandoz Group Sandoz Group agreed US settlements totaling US$478.5 million related to generic drug pricing investigations, reducing a long running source of legal uncertainty.Narrative Update • Aug 02
SDZ: Upgraded GLP-1 Ambitions Will Still Face Earnings And Multiple Pressure
Analysts have trimmed their price target for Sandoz Group to around CHF53 from about CHF54, citing updated assumptions for fair value, revenue growth, profit margin and future P/E that align with the recent upgrade highlighted in Street research. What’s in the News for Sandoz Group Sandoz Group received marketing authorisation in Brazil for Owozy, a semaglutide treatment for type-2 diabetes.Narrative Update • Jul 10
SDZ: Elevated Biosimilar Ambitions Will Face Fragile Earnings And Multiple Compression Risk
Analysts have nudged their price expectations higher for Sandoz Group, with the updated fair value estimate moving from about CHF 47.30 to roughly CHF 54.20, as they adjust assumptions around revenue growth, profit margins and the stock's future P/E in light of recent mixed target changes and an upgrade in Street research. Analyst Commentary Street research on Sandoz Group has been mixed, with some firms lifting their targets and others trimming expectations.Narrative Update • Jun 26
SDZ: Mixed Rating Shifts And Biosimilar Hub Investments Will Shape Future P/E
The analyst price target for Sandoz Group has been revised to CHF 70.74, reflecting updated views on fair value, revenue growth, profit margins, and future P/E after a mix of recent target cuts, target hikes, and an upgrade from major banks. Analyst Commentary Recent Street research on Sandoz Group shows a mix of optimism and restraint, with major banks adjusting their views on valuation, execution, and growth expectations.Analysis Article • Jun 19
Sandoz Group (SWX:SDZ) Stock Could Be 2% Overvalued After Ljubljana Biosimilar Centre Launch
Sandoz Group (SWX:SDZ) has opened a new biosimilar development centre in Ljubljana, Slovenia, a fully digitally integrated US$99 million facility that expands its in house capabilities across drug substance and drug product development. See our latest analysis for Sandoz Group. Set against this investment in Ljubljana, Sandoz Group’s 1 day share price return declined 1.60% to CHF67.68, while its year to date share price return of 18.28% and 1 year total shareholder return of 57.12% suggest...Narrative Update • Jun 11
SDZ: Elevated Biosimilar Ambitions Will Face Tighter Execution And Margin Scrutiny
Analysts have lifted their CHF price target on Sandoz Group to reflect a fair value shift from about CHF 45.23 to roughly CHF 47.30, citing updated assumptions on revenue growth, margins, and future P/E expectations shaped by recent upgrades, downgrades, and target changes across the Street. Analyst Commentary Recent Street research on Sandoz Group has been mixed, with some firms expressing confidence through upgrades and higher price targets, while others are more cautious.Narrative Update • May 28
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have adjusted the Sandoz Group price target slightly higher, with the updated fair value estimate moving from about CHF 66.01 to CHF 66.36 as they factor in modestly different assumptions for growth, margins and future P/E, following a mix of recent upgrades, initiations and target changes across the Street. Analyst Commentary Recent research on Sandoz Group reflects a mix of optimism and caution, with several firms adjusting ratings and price targets in different directions.Narrative Update • May 01
SDZ: Mixed Rating Shifts And Biosimilar Deals Will Shape Future P/E
The updated analyst price target for Sandoz Group has been revised by approximately CHF 1 higher, reflecting modestly adjusted assumptions around fair value, revenue growth, profit margins and future P/E as analysts balance recent target changes and rating shifts across major banks. Analyst Commentary Recent Street research around Sandoz Group shows a mix of optimism on the company’s long term potential and caution on how current pricing and expectations line up with execution risks.Narrative Update • Apr 16
SDZ: Elevated Expectations Will Test Execution On Biosimilar Expansion Plans
Analysts have raised the Sandoz Group price target by roughly CHF 2 per share, reflecting a higher assumed fair value. This is supported by a series of recent CHF 3 to CHF 9 target increases from major banks and generally constructive views, despite some rating downgrades.
Narrative Update • Apr 01
SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating
Analysts have lifted the price target for Sandoz Group from CHF 60.37 to CHF 81.99, citing recent initiations, upgrades and target increases that highlight a higher assumed future P/E multiple and slightly improved profit margin expectations, despite more measured revenue growth assumptions. Analyst Commentary Recent Street research on Sandoz Group presents a mixed picture, but there is a clear strand of optimism around execution, earnings quality and the scope for the shares to support higher valuation multiples.Narrative Update • Mar 18
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have lifted the Fair Value estimate for Sandoz Group from CHF 62.57 to CHF 65.45. This reflects a series of higher Street price targets around CHF 62 to CHF 75 and updated assumptions for modestly higher revenue growth, a slightly lower profit margin profile, and a higher future P/E multiple.Narrative Update • Mar 04
SDZ: Mixed Rating Shifts And Biosimilar Pipeline Progress Will Shape Future P/E
Analysts have lifted their fair value estimate for Sandoz to about CHF 63, reflecting updated assumptions for slightly lower revenue growth, a higher profit margin and a modestly lower future P/E, along with recent mixed rating changes and higher price targets in the CHF 70 to CHF 75 range. Analyst Commentary Recent Street research on Sandoz shows a mix of optimism and caution, with price targets now clustering in the CHF 70 to CHF 75 range and ratings shifting closer to neutral.Narrative Update • Feb 18
SDZ: Richer Future P/E Assumptions Will Test Biosimilar Execution Confidence
Our latest narrative update on Sandoz Group reflects a higher implied fair value of CHF 58.42, up from CHF 52.75, supported by recent analyst price target increases and a willingness to assign a richer future P/E multiple. Analyst Commentary Recent Street research around Sandoz Group has centered on a series of price target revisions and at least one rating upgrade, which together frame how the analyst community is thinking about valuation, execution risk, and growth potential.Narrative Update • Feb 03
SDZ: Elevated Expectations Will Confront Ongoing Execution And Manufacturing Setbacks
Analysts have raised their average price target on Sandoz Group by CHF 3 to CHF 60, citing updated assumptions for revenue growth, profit margins and future P/E, in line with recent target increases from several major banks. Analyst Commentary Recent Street research on Sandoz Group has largely focused on recalibrating price targets to reflect updated views on revenue growth, profitability and valuation multiples.Narrative Update • Jan 20
SDZ: Rising Biosimilar Pipeline Will Face Ongoing Execution And Manufacturing Risks
Narrative Update The updated analyst price target for Sandoz Group reflects a modestly lower fair value estimate alongside slightly higher revenue growth and profit margin assumptions. Recent Street research citing price target moves to CHF 60 and CHF 70 indicates that analysts see room for the shares to better reflect these revised expectations.Narrative Update • Jan 06
SDZ: Elevated Biosimilar Ambitions Will Face Ongoing Execution And Manufacturing Risks
Analysts have lifted their average price targets on Sandoz Group into a CHF 49 to CHF 70 range, and our updated fair value of CHF 44.42 nudges slightly lower as higher assumed profit margins and revenue growth are offset by a reduced future P/E multiple. Analyst Commentary Recent Street research on Sandoz Group shows a cluster of higher price targets, with targets in the CHF 49 to CHF 70 range.Narrative Update • Dec 21
SDZ: Elevated Expectations Will Face Execution Risks In Biosimilars Expansion
Sandoz Group's analyst price target has been lifted by roughly CHF 6.50 to around CHF 60, as analysts now factor in stronger revenue growth, modestly higher profit margins, and a richer forward valuation multiple. Analyst Commentary Recent Street research has been broadly constructive on Sandoz Group, with several major firms lifting their price targets into the CHF 49 to CHF 60 range and maintaining positive ratings.Narrative Update • Dec 07
SDZ: Biosimilar Launch Execution Will Shape Future Multiple And Risk Balance
Sandoz Group’s analyst price target has been nudged higher, with fair value estimates rising by about CHF 1.10 to CHF 52.75 as analysts point to sustained revenue growth expectations and a modestly higher future P E multiple, despite slightly lower margin forecasts. Analyst Commentary Bullish analysts have recently raised their price targets into the CHF 55 to CHF 60 range, signaling growing confidence that Sandoz can sustain above market growth and support a higher valuation multiple.Narrative Update • Nov 23
SDZ: Sustained Revenue Momentum And Margin Focus Will Shape Fair Value Ahead
The analyst consensus price target for Sandoz Group has increased to CHF 60 from CHF 55. Analysts cite improved margin outlook and sustained revenue growth as key factors supporting the upward revision.Narrative Update • Nov 09
SDZ: Recent US Launch and European Expansion Will Influence Near-Term Performance
The average analyst price target for Sandoz Group has increased from CHF 50.33 to CHF 52.05, reflecting improved revenue growth forecasts and recent supportive analyst research updates. Analyst Commentary Recent analyst updates reflect a mix of optimism and caution regarding Sandoz Group's valuation, growth prospects, and execution.Narrative Update • Oct 26
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
The analyst consensus price target for Sandoz Group rose modestly, increasing from CHF 50.20 to CHF 50.33. Analysts cited stronger revenue growth and improving profit margins in their updated outlooks.Narrative Update • Oct 12
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
The analyst price target for Sandoz Group has increased by CHF 0.81. This reflects positive sentiment from analysts who cite strong revenue growth and continued profitability improvements as supporting factors.New Narrative • Aug 17
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.Shareholder Returns
| SDZ | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 2.8% | 3.9% | 1.3% |
| 1Y | 43.9% | 28.3% | 13.7% |
Return vs Industry: SDZ exceeded the Swiss Pharmaceuticals industry which returned 28.3% over the past year.
Return vs Market: SDZ exceeded the Swiss Market which returned 13.7% over the past year.
Price Volatility
| SDZ volatility | |
|---|---|
| SDZ Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: SDZ has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: SDZ's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 20,000 | Richard Saynor | www.sandoz.com |
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms.
Sandoz Group AG Fundamentals Summary
| SDZ fundamental statistics | |
|---|---|
| Market cap | CHF 29.69b |
| Earnings (TTM) | CHF 530.97m |
| Revenue (TTM) | CHF 9.60b |
55.9x
P/E Ratio3.1x
P/S RatioIs SDZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SDZ income statement (TTM) | |
|---|---|
| Revenue | US$11.68b |
| Cost of Revenue | US$6.08b |
| Gross Profit | US$5.60b |
| Other Expenses | US$4.95b |
| Earnings | US$646.00m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.49 |
| Gross Margin | 47.94% |
| Net Profit Margin | 5.53% |
| Debt/Equity Ratio | 65.0% |
How did SDZ perform over the long term?
See historical performance and comparisonDividends
1.2%
Current Dividend Yield68%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/18 23:24 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sandoz Group AG is covered by 37 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emily Field | Barclays |
| James Gordon | Barclays |
| Sidhartha Modi | Barclays |